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Heterologous expression of a biosynthesis gene cluster from Amycolatopsis sp. resulted in the 27 
discovery of two unique class IV lasso peptides, felipeptins A1 and A2. A mixture of felipeptins 28 
stimulated proliferation of cancer cells, while having no such effect on the normal cells. Detailed 29 
investigation revealed, that pre-treatment of cancer cells with a mixture of felipeptins resulted in 30 
downregulation of the tumor suppressor Rb, making the cancer cells to proliferate faster. Pre-31 
treatment with felipeptins made cancer cells considerably more sensitive to the anticancer agent 32 
doxorubicin, and re-sensitized doxorubicin resistant cells to this drug. Structural characterization 33 
and binding experiments showed an interaction betwen f lipeptins resulting in complex 34 
formation, which explains their synergistic effect. This discovery may open an alternative avenue 35 




Lasso peptides represent a family of ribosomally synthesized and post-translationally modified 40 
peptides, (RiPPs, Arnison et al., 2013; Maksimov et al., 2012; Hegemann et al., 2013; Tietz et 41 
al., 2017) whose biosynthetic gene clusters (BGCs) are present in many bacterial genomes 42 
(Hegemann et al., 2015; Mevaere et al., 2018). In recent years, peptide-based bioactive 43 
compounds have attracted considerable attention becaus  of their high specificity to molecular 44 
targets and because they can relatively easy be re-d signed by means of chemical synthesis 45 
and/or genetic engineering (Hegemann et al., 2019; de Veer et al., 2019; Pu et al., 2019; Habault 46 
and Poyet, 2019). Lasso peptides are small peptides (20 amino acids long, on average) of a 47 










residues established when the amino group of the N-terminus forms an isopeptide bond with the 49 
carboxyl side-chain of a glutamic or aspartic acid residue, (ii)  the C-terminal tail  trapped within 50 
the ring either by bulky amino acids or disulfide bridges, or both (Arnoson et al., 2013; 51 
Hegemann et al., 2015; Li et al., 2015a; Li et al., 2015b). 52 
Lasso peptides are divided into four classes based on the number and position of disulfide 53 
bridges that are important structural features of these RiPPs (Tietz et al., 2017). Class I lasso 54 
peptides have two disulfide bridges that link the treaded tail above and below the macrolactam 55 
ring. Class II peptides have no disulfide bridges but have a “steric plug” composed of bulky 56 
amino acids on either side of the macrolactam ring to help stabilize the fold (Allen et al., 2016; 57 
Hegemann et al., 2016; Hegemann, 2020). Class III and IV have only one disulfide bridge. In 58 
class III the disulfide bridge links the tail to the macrolactam ring, whereas in class IV the 59 
disulfide bridge is located at the tail itself. So far only two class IV peptides have been 60 
characterized, LP2006 from the actinomycete bacterium Nocardiopsis alba (PDB accession 61 
number 5JPL; Tietz et al., 2017), and pandonodin from Pandoraea norimbergensis (PDB 62 
accession number 6Q1X; Cheung-Lee et al., 2019). 63 
Bioactivities exhibited by lasso peptides are of definite interest in terms of drug discovery. Some 64 
bacterial lasso peptides, such as microcin J25 and c pistruin, inhibit RNA polymerase in Gram-65 
negative bacteria and thus have antibiotic activity (Braffman et al., 2019). Others act as 66 
antagonists of glucagon receptor (BI-32169; Knappe et al., 2010), endothelin B receptor (RES-67 
701; Morishita et al., 1994) or have inhibitory activity in a cell invasion assay with cancer cells 68 
(sungsanpin; Um et al., 2013).    69 
The minimal set of genes in a lasso peptide BGC encodes a precursor peptide (A) that contains 70 
an N-terminal leader and a C-terminal core region sequence, a leader peptide recognition protein 71 










encode fused B1-B2 proteins. Furthermore, some lasso peptide BGCs can also contain genes for 73 
ABC transporters (D), isopeptidases or other additional modification enzymes (Hegemann et al., 74 
2015; Tietz et al., 2017). Significant progress has recently been made in characterization of these 75 
proteins, as reported by Yan et al. (2012), DiCaprio et al. (2019), Choudhury et al. (2014), Fage 76 
et al. (2016), and Zhu et al. (2016). A study from 2017 provided good insight into the 77 
biosynthetic landscape of lasso peptides by identifyi g BGCs in available bacterial genomes and 78 
predicting a total of 1,315 lasso peptide sequences from them (Tietz et al., 2017). This number 79 
has nearly doubled in more recent work by de los Santos, who has developed a neural network 80 
for identification of RiPP precursor peptides (de los Santos, 2019). Chemical synthesis of lasso 81 
peptides is very difficult, and only one example has been reported recently (Chen et al., 2019), 82 
suggesting that the best way to produce such peptides and test their biological activities and 83 
potential as drug leads is to isolate them after biosynthesis in vivo.  84 
The relatively small size of lasso peptide BGCs makes heterologous expression an attractive 85 
approach for the production of this class of compounds (Hegemann et al., 2013; Li et al., 2015b; 86 
Mevaere et al., 2018; Martin-Gomez et al., 2018). Vast majority of lasso peptides are of 87 
proteobacterial origin with only a few examples from actinomycetes. Except for the archetype 88 
lasso peptide J25 that was discovered in its native host, Escherichia coli, proteobacterial lasso 89 
peptides have typically been produced via heterologous expression. Sviceucin is the only lasso 90 
peptide from an actinomycete bacterium that has been produced via heterologous expression in 91 
considerably high quantities (Li et al., 2015a). Therefore, further attempts on expression of lasso 92 
peptide BGCs must be pursued in order to gain access to the diversity of lasso peptides, 93 
especially from actinomycete bacteria. This is particularly relevant for class IV lasso peptides, 94 










In this work, we present the successful genome mining of a newly isolated Amycolatopsis sp., 96 
leading to the heterologous expression, purification, structural and biological characterization of 97 
two class IV lasso peptides exhibiting unique synergistic biological activity, which may prove 98 
useful in combinational cancer chemotherapy. 99 
 100 
RESULTS AND DISCUSSION 101 
 102 
Amycolatopsis sp. YIM10 metabolites and genome analyses. Amycolatopsis sp. YIM10 was 103 
isolated from a rare earth mine of Bayan Obo, Inner Mongolia, China, and taxonomically 104 
identified by means of 16S rRNA gene sequencing. Cultivation of this isolate in different 105 
conditions revealed its ability to produce various tiglosides and 1,2,4-trimethoxynaphthalene, as 106 
suggested by LC-MS analyses (Figures S1-S4, Supplemental Information). While these natural 107 
products have been described previously (Guo et al., 2012; Rycroft et al., 1998), the latter has 108 
never been isolated from a bacterium before. The structures of these compounds were also 109 
confirmed using NMR spectroscopy (Figures S5-S6, Supplemental Information). No compounds 110 
with strong antimicrobial activity could be identified in these initial experiments. Keeping in 111 
mind the reported potential of Amycolatopsis spp. to produce bioactive secondary metabolites, 112 
the genome of YIM10 was completely sequenced (GenBank accession number CP045480, Table 113 
S3), and found to consist of a circular chromosome f 10.31 Mb and a 39.9 Kb plasmid. The 114 
genome was analyzed with antiSMASH 5.0 software (Blin et al., 2019), which identified at least 115 
44 secondary metabolite BGCs. Several of these BGCs appear to be unique and could not be 116 
identified in the publicly available genomes of other bacteria (Table S4, Supplemental 117 










the genome of recently described Amycolatopsis albispora WP1 isolated from marine sediment 119 
(Wu et al., 2018), suggesting that these strains are closely related. 120 
Given that the genome of Amycolatopsis sp. YIM10 contains uncharacterized BGCs and 121 
therefore may have a potential to produce previously ndescribed compounds, it was regarded as 122 
an excellent candidate for genome mining. First, this strain was evaluated as a possible subject 123 
for genetic manipulation. However, YIM10 was found to be resistant to all the antibiotics used as 124 
selection markers in actinomycetes, in particular apramycin, hygromycin, thiostrepton, 125 
kanamycin and puromycin. Thus, establishing a gene transfer system for this bacterium appeared 126 
problematic. Considering this, cloning and expression of BGCs in a heterologous host seemed 127 
like the only strategy to circumvent the problem. Therefore, a YIM10 fosmid genome library was 128 
constructed (Supplemental Information, Transparent Methods). We were particularly interested 129 
in expressing BGC21, which was predicted to govern biosynthesis of two class IV lasso peptides 130 
(MiBIG accession number BGC0002064). This BGC spans ~10 kb and contains all the main 131 
genes for the biosynthesis of this class of RiPPs.  132 
Screening of the genome library using pooled PCR with primers designed for flanking and 133 
central regions of BGC21 led to the identification of a single fosmid containing the entire cluster. 134 
BGC21 (Figure 1) harbors two genes encoding precursor peptides (filA1 and filA2), as well as 135 
genes for the proteins involved in the leader peptid  recognition and cleavage (filB1 and filB2), 136 
the macrolactam ring formation (filC), putative oxidoreductase-catalyzed reactions (filE), 137 
transport (filD1 and filD2), and transcriptional regulation (filR1). 138 
A cassette containing an oriT sequence and integration site int-attPφC31 allowing conjugative 139 
transfer of the construct into Streptomyces bacteria and stable genomic integration, respectivly, 140 
was incorporated into the identified fosmid using λ RED recombineering (Supplemental 141 










into Streptomyces coelicolor M1154 engineered for heterologous expression of exg nous BGCs 143 
(Gomez-Escribano and Bibb, 2011) and Streptomyces albus J1074. The resulting recombinant 144 
strains were cultivated in different liquid and solid media, but no lasso peptide production could 145 
be detected in these conditions. 146 
Next, the gene filR1 encoding a transcriptional regulator of the SARP family, was cloned into the 147 
plasmid pSOK806 under control of the strong constitutive promoter ermEp* (Mevaere et al., 148 
2018). The construct was conjugated into the abovementioned Streptomyces hosts that harbored 149 
integrated recombinant fosmid with BGC21. The constitutive overexpression of the FilR1 SARP 150 
regulator apparently triggered the production of both predicted lasso peptides in the two 151 
Streptomyces hosts when cultivated in liquid MYM medium (Figures S7-S8, Supplemental 152 
Information). The detected lasso peptides were designated felipeptins A1 and A2, and predicted, 153 
based on the sequence data, to be composed of 18 and 17 amino acids, respectively. 154 
Given that the S. coelicolor M1154 host has a cleaner metabolic background compared to that of 155 
S. albus J1074, and virtually no differences in lasso peptides yields were found between the two 156 
strains (data not shown), it was decided to work futher only with the former recombinant strain. 157 
 158 
Structure elucidation by LC-MS and NMR confirms the identity of two class IV lasso 159 
peptides. Up-scaled fermentation and optimization of the purification protocol resulted in 160 
production yields of 12 mg/L of felipeptin A1, and 7 mg/L of felipeptin A2 (see Methods). These 161 
yields are significantly higher than those usually obtained after heterologous expression of lasso 162 
peptides BGCs (Li et al., 2015a; Mevaere et al., 2018; Martin-Gomez et al., 2018). Most likely, 163 
this is due to overexpression of the SARP regulator encoded by the felipeptins BGCs, which 164 
apparently controls expression of all other biosynthetic genes in the cluster.  The measured 165 











2+, m/z 1009.4616, Δ = 2.4 ppm) and felipeptin A2 (HRESIMS m/z 922.9145 167 
[M+2H]2+; calculated for C81H119N23O23S2
2+, m/z 922.9140, Δ = 0.5 ppm) matched well with the 168 
peptide sequences GSRGWGFEPGVRCLIWCD and GGGGRGYEYNKQCLIFC predicted 169 
from the filA1 and filA1 gene products, respectively, provided that two macrocycles are formed 170 
(Figure S8, Supplemental Information). The purity of felipeptins was verified using HPLC and 171 
LC-MS (Figures S9 and S10, Supplemental Information).  172 
The structures of both felipeptins (Figure 2) were lucidated using an NMR-based approach, 173 
with DMSO as the solvent (see Methods). The structues depict an 18-mer peptide (felipeptin 174 
A1) and 17-mer peptide (felipeptin A2) with a looped-handcuff topology. Both peptides have an 175 
eight amino acid macrolactam ring at the N-terminus formed by condensation of the side-chain 176 
of Glu8 and the free N-terminus of Gly1. The formation of the isopeptide bond is confirmed by 177 
the long range nuclear Overhauser effect (NOE) peak b tween these two residues. For both 178 
felipeptins, threading of the loop region through the macrolactam ring is confirmed by the long-179 
range NOEs (Hα Trp5–Hα Arg12 and   HN Gly6–Hα Arg12). Formation of a disulfide bridge 180 
(Cys13-Cys17) in both felipeptins was confirmed by long-range NOEs between Hα of Cys17 and 181 
Hβ of Cys13. This disulfide bond might serve as a stabilizing feature by “trapping” the tail in 182 
position.  Other structural features that might serve as steric locks are Val11 (in A1) and Gln12 183 
(in A2) above the macrolactam ring, as well as Arg12 and Leu14 (in A1) and Leu14 (in A2) 184 
below the ring. The A1 and A2 structures have been deposited in the Protein Data Bank under 185 
the accession IDs 6XTH and 6XTI, respectively.  186 
Structural features were also confirmed by the spectra of the two lasso peptides,  obtained after 187 
tandem MS (Rosengren et al., 2004; Jeanne Dit Fouque et al., 2019),which showed a series of 188 
abundant a-, b-, and y-type peptide fragment ions cvering the linear chain encompassing amino 189 










Gly formed after removal of leader peptides and the sid -chain of Glu8 on one side, as well as 191 
the formation of a second macrocycle via a disulfide bridge between Cys-residues in positions 13 192 
and 17 (Figure 3).  193 
 194 
The proposed biosynthesis of the felipeptins A1 and A2 requires FilB1, FilB2, FilC and 195 
FilE for mature lasso peptide formation. Based on the current knowledge on the functions of 196 
the lasso peptide biosynthesis enzymes, and the pres nc  of a gene filE encoding an 197 
oxidoreductase, the biosynthesis of felipeptins waspredicted as shown in Figure 4. 198 
According to the proposed biosynthetic pathway, the FilB1 protein recognizes the precursor 199 
peptides, products of filA1 and filA2 genes, and guides them to the peptidase FilB2, which 200 
cleaves off leader peptides (DiCaprio et al., 2019; Koos and Link, 2019). Immediately after 201 
cleavage, the lasso cyclase FilC forms a macrolactam ring and assists in the lasso fold formation. 202 
The last step in the biosynthesis is most likely accomplished by an oxidoreductase FilE, which 203 
forms disulfide bridges, stabilizing the final struct res. Interestingly, database searches for 204 
proteins similar to FilE revealed only those with less than 55% identity, suggesting this 205 
oxidoreductase being rather unique. 206 
Since the only other member of class IV lasso peptid s biologically characterized, LP2006, 207 
displayed antibacterial activity, we tested felipeptins A1 and A2 against a panel of different 208 
Gram-positive bacteria in liquid media-based assays in order to determine minimal inhibitory 209 
concentrations. The results obtained suggest that felipeptins and their combination do not exhibit 210 
antibiotic properties, except in the cases of Streptococcus pyogenes and Streptococcus 211 
pneumoniae, where felipeptin A1 and the 1:1 A1+A2 mixture showed weak antibacterial activity 212 
(Table S5, Supplemental Information). Interestingly, in the case of S. pyogenes, only a mixture 213 










diffusion assay performed using Bacillus subtilis as test organism (Figure S11, Supplemental 215 
Information).  216 
 217 
Felipeptins A1 and A2 exert a unique synergistic effect on cancer cells. In order to evaluate 218 
other possible bioactivities of felipeptins A1 and A2, we tested the effect of a range of 219 
concentrations of felipeptins and their combination in cell viability assays using several cancer 220 
cell lines of different origin, including colon carcinoma HCT116, melanoma A375 and breast 221 
carcinoma MCF7, in comparison to normal cells, the human fibroblast cell line BJ and bone 222 
marrow-derived mesenchymal stem cells (MSC). While individual peptide treatments had 223 
marginal and statistically insignificant effects on the number of viable MCF7, HCT116 and 224 
A375 cells, their combination at certain ratios significantly increased the number of viable cancer 225 
cells in three cell lines (Figure 5A-C, left panels and Figure S12A-B). The effect of felipeptins 226 
combinations at several doses was synergistic, as shown in Figures 5A-C (green squares). In 227 
contrast, the effect of felipeptins on the growth rate of normal cells, BJ and MSC, was weak and 228 
without synergistic effect (Figure 5D and Figure S12C). 229 
Since the increased number of cells could be due to either lower rate of cell death or higher rate 230 
of cell proliferation, we investigated the effect of felipeptins on cell cycle distribution using 231 
fluorescence-assisted cell sorting (FACS) of propidium-iodide stained cells (Figure 6A-C). 232 
While no change in the fraction of dead cells (subG1 fraction, <2N DNA content) could be 233 
observed, a decrease of cells in G1 (cell cycle preparatory phase, 2N DNA content) 234 
concomitantly with the increase of cells with >2N DA content, i.e., cells in replication (S) and 235 
cell division (G2/M) phases was evident. These datacle rly indicated an enhanced rate of 236 










To better understand the mechanism of pro-proliferative activity of felipeptins, we tested the 238 
involvement of tumor suppressors p53 and Rb, the two key factors that control the decisions of 239 
cells to proliferate (Hanahan and Weinberg, 2011). We addressed the involvement of p53 by 240 
using two cancer cell lines, MCF7p53KO and A375p53KO, in which the p53 gene was deleted 241 
by means of CRISPR-Cas9-mediated gene editing. However, the deletion of p53 did not 242 
significantly affect the pro-proliferative activity of felipeptins and their combinations (Figure 243 
S12D and E, Supplemental Information). Importantly, the observed statistically significant 244 
changes in the proportion of cells in different phases of the cell cycle, although minor, were 245 
qualitatively and quantitatively similar to those exhibited upon deletion of the gene for the 246 
retinoblastoma protein Rb (Brugarolas et al., 1998). In addition, we found a significant decrease 247 
in the level of the Rb protein and phosphorylated Rb upon felipeptin treatment in A375 cells, as 248 
assessed by immunoblotting (Figure 6D). Taken together, our data suggest that the inhibition of 249 
Rb is involved in stimulation of proliferation by felipeptins. 250 
The concept that quiescent cancer stem-like cells (CSCs) within solid and hematological cancers 251 
confer resistance to chemo- and irradiation therapy, which preferentially targets rapidly 252 
proliferating cells, is currently widely accepted (Hanahan and Weinberg, 2011; Brown et al., 253 
2017). Based on our data on stimulation of the cancer cell proliferation by felipeptins, we 254 
addressed the question of whether pre-treatment with fel peptins can increase the cytotoxic 255 
activity of the widely used chemotherapeutic drug doxorubicin (DOX). Importantly, we found 256 
that pre-treatment of MCF7 and A375 cells with felip ptins significantly and synergistically 257 
increased the efficiency of cancer cell suppression by doxorubicin (Figure 7A, B, left panels). 258 
The quantification of the synergistic effect of combination ratios is presented in the left panels In 259 
Figure 7 A, B (green squares). Further confirmation of the potentially beneficial effect of pre-260 










experiment, the A375 cells were pre-treated with a combination of 6.25 µM and 12.5 µM of 262 
felipeptins for 72h, followed by 72h DOX treatment. The number of cancer cell colonies was 263 
decreased much more efficiently by DOX upon pre-treatment with felipeptins (Figure 7C), 264 
demonstrating a remarkable increase in sensitivity towards DOX in comparison with the non-265 
pretreated cells. Furthermore, the number of cells in the colonies was considerably lower in the 266 
felipeptins pre-treated samples. A number of studies have found that DOX has high propensity to 267 
select for drug-resistant cancer stem cells in previously differentiated cancer cells of various 268 
human solid tumors, including lung and breast carcinoma, neuroblastoma and osteosarcoma 269 
(Martins-Neves et al., 2018). Calcagno et al. have demonstrated that prolonged exposure of the 270 
MCF-7 breast cancer cells to doxorubicin selects for cells with a drug-resistant phenotype, 271 
enriched in stem cells with increased invasiveness and tumorigenicity (Calcagno et al., 2010). 272 
Following the previously described protocol (Calcagno et al., 2010), we selected DOX-resistant 273 
MCF7 cells and tested whether stimulation of their growth by felipeptins will overcome 274 
resistance to DOX (Figure 7D). As shown in Figure 7E, cells pre-treated with felipeptines were 275 
much more sensitive to the second treatment with DOX. Felipeptins decreased the number of 276 
drug-resistant colonies almost 4-fold. Moreover, as c n be seen in Figure 7F, the remaining 277 
colonies contained fewer cancer cells, while the phnotype of some of those remaining cells (big, 278 
flat cells) suggests that they entered irreversible growth arrest (senescence), preventing their 279 
recurrent growth. Thus, our data demonstrate that simulating the proliferation of drug-resistant 280 
cancer stem cells by felipeptins re-sensitized them to chemotherapy and overcame drug 281 
resistance.  282 
Notably, the biological effect of combined felipeptins was dependent on the cell type. The 283 
selective effect of felipeptins on different types of cells lead us to speculate that the combination 284 










have differential effects on different types of cells. For example, activin A, which belongs to the 286 
transforming growth factor beta superfamily, can exert both proliferative and anti-proliferative 287 
effects depending on the differentiation stage of the cell and the presence of other growth factors 288 
in the system (Bloise et al., 2019). Further high throughput studies are required to dissect the 289 
exact mechanism of the selective biological activity of felipeptins. 290 
 291 
Synergistic biological effect of felipeptins is likely due to complex formation. In order to 292 
further investigate the synergistic effect between felipeptins A1 and A2, we performed an NMR 293 
titration experiment to measure the strength of the interaction (dissociation constant; Kd) between 294 
them (Supplemental Information). 13C-HSQC spectra of felipeptin A2 were recorded before and 295 
after addition of felipeptin A1. Upon increasing the concentration of felipeptin A1, we observed 296 
chemical shift perturbation in certain residues (side-chains of Arg5, Tyr7, Lys11 and Ile15; 297 
backbone of Lys11) in felipeptin A2. These affected r sidues were confirmed by chemical shift 298 
perturbations observed in a 15N-HSQC spectrum recorded at the end of the titration 299 
(Supplemental Information, Figure S12). These chemical shift perturbations indicate a change in 300 
the chemical environment of the observed 1H-13C atom pairs that were used to estimate a Kd = 301 
0.3 ± 0.2 mM for the interaction (Figure S12). The amino acid specific locations of the highest 302 
chemical shift perturbations were used to guide the docking of felipeptins A1 and A2 using 303 
HADDOCK (van Zundert et al., 2016).  304 
Figure S12 (Supplemental Information) shows a HADDOCK model, where the ring of one 305 
felipeptin interacts with the tail of the other (see figure text of Figure S12 for further discussion). 306 
While the NMR data fits best with a model in which felipeptins interact in a 1:1 ratio, we can't 307 
rule out the possibility of a model where felipeptins nteract in other ratios. NMR studies were 308 










Methods). While the observation of the interaction between felipeptins under these conditions 310 
does not entail the existence of an interaction under physiological conditions, it does not rule it 311 
out either. 312 
Whatever the molecular mechanism behind the specific st mulation of cancer cell proliferation 313 
by felipeptins is, this unique biological activity may open interesting possibilities for 314 
combinational cancer therapy. Accumulated experimental evidence increasingly supports the 315 
notion that the persistence of quiescent subpopulations of cancer cells, including cancer stem 316 
cells (CSCs), cause relapse after initially successful chemotherapeutic treatment (Battle and 317 
Clevers, 2017). However, targeting quiescent CSCs remains a major challenge. A possible 318 
strategy could be to 'wake up' this cell population o increase its susceptibility to chemotherapy, 319 
as it has been demonstrated by genetic means in experimental models of chronic myeloid 320 
leukemia (Takeishi et al., 2013). 321 
 322 
Thermal and proteolytic stability of felipeptins. Considering presumed potential of felipeptins 323 
in being used in therapy, it appeared necessary to tes  their thermal and proteolytic stability. To 324 
assess the thermal stability of the felipeptins and the stabilizing role of the disulfide bond, 325 
aqueous solutions were incubated at 95°C for 20h in t e absence and presence of the reducing 326 
agent dithiothreitol (DTT). (Allen et al., 2016; Zong et al., 2017; Hegemann, 2020). Felipeptin 327 
A1 showed no sign of thermal unthreading after 20h at 95°C, even though partial hydrolytic 328 
cleavage of the C-terminal Asp18 was already observed. In the presence of DTT, not only 329 
reduction of the disulfide bond but also further chemical cleavage was detected, proving the 330 
stabilizing role of the disulfide bond (Fig. S14). 331 
Felipeptin A2 also showed remarkable thermal stabili y, but the appearance of an additional peak 332 










The MS data for this additional peak proof identical m ss and the MS/MS spectrum shows 334 
identical fragment ions that were, however, detected with altered relative intensities, indicating a 335 
different peptide fold (Fig. S16). Both peptides were stable towards carboxypeptides B and Y, 336 
which might as well be attributed to the lasso-fold (Fig. S17, S18) as well as to the disulfide 337 
bond close the C-terminus. Considering the size of the macrocycle formed by the disulfide bond 338 
(Fig. 2), it can be assumed that thermal unthreading proceeds via the tail pulling mechanism 339 
only, but which structural features determine the ev n higher stability of felipeptin A1 compared 340 
to A2 requires further detailed studies (Hegemann, 2020). 341 
The high thermal and proteolytic stability observed for the felipeptins is definitely a big 342 
advantage when considering up-scaled biotechnological production and potential medical 343 
applications. Most of the current chemotherapeutic agents used for cancer treatment are designed 344 
to target rapidly dividing cancer cells, which are thus becoming more vulnerable to cytotoxic 345 
agents compared to normal cells. However, in many cses seemingly successful treatments of 346 
cancers still end up in relapse, owing to the dormant c ncer cells that survive the treatment in a 347 
quiescent state. Pre-treatment of cancer cells with felipeptins sensitizes them to doxorubicin, a 348 
widely used chemotherapeutic agent, and may provide an opportunity to reduce the dosage of 349 
this cytotoxic agent and thereby minimize side effects. Moreover, pre-treatment of doxorubicin-350 
resistant cancer cells with these lasso peptides makes them again sensitive to this drug. Taken 351 
together, our results suggest a possibility of an alternative direction in cancer therapy based on a 352 
combination of proliferation-inducing treatment and cytotoxic drugs targeting rapidly dividing 353 
cells.    354 
 355 










We note three limitations of this study. One relates to the exact mechanism of action of 357 
felipeptins on cancer cells, which appears to be due to the reduction in the amount of tumor 358 
suppressor protein Rb. However, how this reduction is achieved, and whether the felipeptins 359 
enter the cells or act on a membrane-anchored receptor is not known. Further studies, which 360 
would include more characterized cell lines, transcriptomics and proteomics can clarify this 361 
issue. The second limitation is due to the low solubility of lasso peptides in water, which 362 
prevented the studies on complex formation in the aqueous solutions mimicking cellular 363 
environment. Hence, only formation of the complex in DMSO-based solution could be shown.  364 
The third limitation relates to an idea of using the felipeptins in eukaryotic cell suspension 365 
cultures producing pharmaceutical proteins, where addition of lasso peptides could support more 366 
vigorous growth and hence increase the efficiency of the production process. This direction of 367 
research has not yet been addressed in the current study, but deserves proper investigation. 368 
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FIGURE LEGENDS 631 
 632 
Figure 1. Lasso peptide biosynthesis gene cluster from Amycolatopsis sp. YIM10: organization 633 
of genes and predicted functions of their products. 634 
Figure 2. NMR ensemble structures of (A) felipeptin A1 PDB:6TXH and (B) A2 PDB:6TXI. 635 
The structures depict the looped-handcuff topology stabilized by a disulfide bridge, characteristic 636 
of class IV lasso peptides. In both structures, amino-acids G1-E8 in the macrolactam ring are 637 
colored lighter, and the disulfide bridges, C13-C17, are colored yellow. The amino acid 638 
sequences and lowest energy conformers for felipeptins A1 (C) and A2 (D) are also shown. 639 
Figure 3. HRESIMS/MS spectra of the [M+2H]2+ ions of felipeptin A1 at m/z 1009.4640 (A) 640 
and felipeptin A2 at m/z 922.9145 (B). The fragmentation, occurring mainly in the linear region 641 










Figure 4. Proposed felipeptins biosynthesis pathway. 643 
Figure 5. Synergistic induction of cancer cell proliferation by felipeptins. (A-D) Left panels, 644 
heatmaps show changes of the number of viable cells upon 72 h treatment with different doses of 645 
felipeptins and their combinations at a 2-fold serial dilution (as indicated in the figures) in cancer 646 
cell lines MCF7 (A), A375 (B), HCT116 (C) and normal cells, BJ fibroblasts and bone marrow-647 
derived mesenchymal stem cells MSC (D), measured using rezasurin assay and normalized to 648 
DMSO control. Red indicates increased cell number, white – no change, blue – decreased cell 649 
number.  Right panels, heatmaps show Highest Single A ent (HSA) reference model score, 650 
indicated by green color (A-D). Data presented as mean log2 from two independent experiments 651 
performed in duplicate. 652 
Figure 6.  Felipeptins stimulate proliferation of cancer cells via inhibition of pRb. (A, C) 653 
Stimulation of cell cycle progression by 24h treatment with felipeptins (green bars, 6.25 µM 654 
each; red bars, 12.5 µM each) as detected by FACS of propidium iodide-stained A375 (A, B) and 655 
HCT116 (C) cell lines. Grey bars, control DMSO treament. Data shown as mean ± SD from two 656 
independent experiments. *p<0.05, unpaired t test. (D) Western blotting for total RB and 657 
phospho-Rb in A375 upon felipeptins treatment for 24 h. β-Actin is used as a loading control. 658 
Figure 7. Felipeptins sensitize cancer cells to doxorubicin and overcome drug resistance of 659 
cancer stem cells. (A,B) Heatmaps (left panels) reflect the number of viable cells in A375 (A) 660 
and MCF7 (B) cell lines, pre-treated with different concentrations of felipeptins for 72h followed 661 
by doxorubicin for another 72h. HAS Synergy scores ( ight panels) are indicated in green color. 662 
Data presented as mean log2 from two independent experiments performed in duplicate. (C) 663 
Long-term viability assay (7-day colony formation) i  A375 cells, pre-treated or not pre-treated 664 
with felipeptins A1+A2 before applying doxorubicin as in (A). Colonies were detected using 665 










untreated control. ** 0.01 ≤ p. (D). Schematic illustration of the experiment. I -Doxorubicin-667 
resistant MCF-7 cancer stem cells were obtained upon 72h treatment by 12.5 nM doxorubicin. II-668 
Their growth was stimulated by combination of felipptins (25 μM each) for 96 h. III- Resulting 669 
colonies were treated by the same doses of DOX or felipeptins or Dox/felipeptins combination 670 
for 5 days. (E) Quantification of drug-resistant colonies obtained as in (D) upon treatment of 671 
DOX or felipeptins or their combination. Colonies were detected using crystal violet staining; 672 
colonies were counted using image J analysis. (F) Representative phase-contrast microscopy 673 









filR1                      transcriptional regulator (SARP family)
filA1 felipeptin A1 lasso peptide precursor 
filA2 felipeptin A2 lasso peptide precursor 
filC asparagine synthase (lasso cyclase)
filB1 PqqD family protein (leader peptide binding)
filB2 transglutaminase-like superfamily protein (leader peptidase)
filE LLM class flavin-dependent oxidoreductase (disulfide bridge formation)
filD1 ABC transporter (lasso peptide efflux)
filD2 ABC transporter (lasso peptide efflux)
filR1    A1 A2            C            B1 B2 E                  D1                       D2
Figure 1. Lasso peptide biosynthesis gene cluster from Amycolatopsis sp. YIM10: organization of genes and 
















Figure 3. HRESIMS/MS spectra of the [M+2H]2+ ions of felipeptin A1 at m/z 1009.4640 (A) and 
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Class IV lasso peptides synergistically induce proliferation of cancer cells and sensitize 
them to doxorubicin 
 
Jaime Felipe Guerrero-Garzón1,‡, Eva Madland2,‡, Martin Zehl3, Madhurendra Singh4, Shiva 
Rezaei4,5, Finn L. Aachmann2, Gaston Courtade2, Ernst Urban6, Christian Rückert7, Tobias 
Busche7, Jörn Kalinowski7, Yan-Ru Cao8, Yi Jiang8, Cheng-lin Jiang8,  Galina Selivanova4*, 




•   Lasso peptides felipeptins from Amycolatopsis sp. produced in a heterologous host  
 
•   Felipeptins synergistically sensitize cancer cells to doxorubicin 
 
•   Synergistic effect on cancer cells appears to be due to complex formation  
 
•   Felipeptins overcome drug resistance of cancer stem cells 
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